Salud financiera de hoja de balance de Inhibrx

Salud financiera controles de criterios 5/6

Inhibrx tiene un patrimonio de los accionistas total de $43.5M y una deuda total de $207.0M, lo que sitúa su ratio deuda-patrimonio en 475.8%. Sus activos y pasivos totales son $307.9M y $264.4M respectivamente.

Información clave

1,799.9%

Ratio deuda-patrimonio

US$208.21m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$252.48m
Patrimonio	US$11.57m
Total pasivo	US$277.01m
Activos totales	US$288.58m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Oct 03

Inhibrx: Potential To Move To Registration Study With INBRX-101

Jun 10

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23

Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results

May 16

What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?

Jan 14

Inhibrx's INBRX-109 wins FDA's Fast Track status

Jan 13

Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors

Jan 05

Need To Know: Analysts Are Much More Bullish On Inhibrx, Inc. (NASDAQ:INBX) Revenues

Nov 22

Inhibrx EPS misses by $0.07

Nov 13

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($295.4M) de INBX superan a sus pasivos a corto plazo ($56.3M).

Pasivo a largo plazo: Los activos a corto plazo de INBX ($295.4M) superan a sus pasivos a largo plazo ($208.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: INBX tiene más efectivo que su deuda total.

Reducción de la deuda: INBX tenía patrimonio neto negativo hace 5 años, pero ahora es positivo y, por lo tanto, ha mejorado.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: INBX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: INBX tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 38.9% cada año

Salud financiera de hoja de balance de Inhibrx

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Executive VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Price target decreased by 20% to US$35.50

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

Consensus revenue estimates increase by 26%

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 85%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Consensus revenue estimates increase by 42%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

Inhibrx: Potential To Move To Registration Study With INBRX-101

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Consensus revenue estimates fall by 17%

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Price target decreased to US$49.67

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased to US$49.67

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020)

Price target increased to US$42.60

Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020)

Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study

Consensus forecasts updated

Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results

First quarter 2021 earnings released: US$0.51 loss per share (vs US$1.05 loss in 1Q 2020)

Consensus forecasts updated

Inhibrx, Inc. Announces Results from the Single Agent Dose Escalation of the Phase 1 Study of INBRX-105

Full year 2020 earnings released: US$3.01 loss per share (vs US$2.83 loss in FY 2019)

Revenue and earnings beat expectations

New 90-day low: US$22.17

Inhibrx, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to INBRX-109

What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?

Inhibrx's INBRX-109 wins FDA's Fast Track status

Inhibrx, Inc. Announces Results from Part 1 of the Phase 1 Dose Escalation Trial of Inbrx-106

Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors

Arecor's Partner Inhibrx Exercises Its Option to License A New Formulation Developed by Arecor

New 90-day high: US$37.42